Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024

Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024

DelveInsight’s, “Acute-Lymphocytic-Leukemia- Pipeline Insight, 2024” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute-Lymphocytic-Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute-Lymphocytic-Leukemia: Understanding

Acute-Lymphocytic-Leukemia: Overview

Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. Lymphocytic means it develops from early (immature) forms of lymphocytes, a type of white blood cell. ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.

The early signs and symptoms of ALL may be like the flu or other common diseases. Some of the common sign and symptoms include weakness or feeling tired, fever or drenching night sweats, easy bruising or bleeding, petechiae (flat, pinpoint spots under the skin, caused by bleeding), shortness of breath, weight loss or loss of appetite, pain in the bones or stomach, pain or feeling of fullness below the ribs, painless lumps in the neck, underarm, stomach, or groin, having many infections.

For the diagnosis of the disease following tests and procedures may be used like Physical exam and health history, Complete blood count (CBC) with differential, Bone marrow aspiration and biopsy.

The four types of standard treatment used for Acute Lymphocytic Leukemia (ALL) are as follows:

Chemotherapy: It is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Radiation therapy: Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing

Chemotherapy with stem cell transplant: Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells

Targeted therapy: Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapy may cause less harm to normal cells than chemotherapy or radiation therapy do.

""Acute-Lymphocytic-Leukemia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute-Lymphocytic-Leukemia pipeline landscape is provided which includes the disease overview and Acute-Lymphocytic-Leukemia treatment guidelines. The assessment part of the report embraces, in depth Acute-Lymphocytic-Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute-Lymphocytic-Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute-Lymphocytic-Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Acute-Lymphocytic-Leukemia.

Acute-Lymphocytic-Leukemia Emerging Drugs Chapters

This segment of the Acute-Lymphocytic-Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press

releases.

Acute-Lymphocytic-Leukemia Emerging Drugs

Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational high-precision cell therapy designed to replace a patient's cancerous blood and immune system with a healthy one while dramatically lowering their risk of developing GvHD and other potentially life-threatening side effects. In the Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of significantly higher GvHD-free, relapse-free survival rates after 1 year, improved relapse-free survival rates and lower rates of chronic GvHD. Currently, the drug is in Phase III stage of its development for the treatment of ALL.

TGRX-814: Shenzhen TargetRx, Inc.

TGRX-814 is a highly selective inhibitor of the BCL2 (over BCL-XL) for the treatment of CLL with or without the del(17p)/TP53 mutation, NHL, SLL, DLBL, MM, etc. Notably, TGRX-814 has an excellent selectivity profile for BCL-XL. TGRX-814 is modified and optimized through classical bioisosterism and molecule simulation technologies. In-vitro and in-vivo assays have shown that TGRX-814 improves oral metabolism, increases in vivo exposure, and reduces compound clearance while maintaining in vitro and in vivo bioactivity. Moreover, TGRX-814 obtained over 2-fold increase in bioavailability compared to the marketed drug Venetoclax, resulting in a significant increase in efficacy. Currently, the drug is in Phase I/II stage of its development for the treatment of ALL.

UCART22: Cellectis

UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development. Currently, the drug is in Phase I stage of its development for the treatment of ALL.

Further product details are provided in the report……..

Acute-Lymphocytic-Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different Acute-Lymphocytic-Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute-Lymphocytic-Leukemia

There are approx. 125+ key companies which are developing the therapies for Acute-Lymphocytic-Leukemia. The companies which have their Acute-Lymphocytic-Leukemia drug candidates in the most advanced stage, i.e. Phase III include, Orca Biosystems, Inc.

Phases

DelveInsight’s report covers around 130+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute-Lymphocytic-Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute-Lymphocytic-Leukemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute-Lymphocytic-Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute-Lymphocytic-Leukemia drugs.

Acute-Lymphocytic-Leukemia Report Insights

Acute-Lymphocytic-Leukemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute-Lymphocytic-Leukemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute-Lymphocytic-Leukemia drugs?

How many Acute-Lymphocytic-Leukemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute-Lymphocytic-Leukemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute-Lymphocytic-Leukemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute-Lymphocytic-Leukemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Orca Biosystems, Inc

Jazz Pharmaceuticals

Shenzhen TargetRx, Inc

Cellectis

ADC Therapeutics S.A.

Kunming Hope of Health Hospital

Beam Therapeutics Inc.

Shenzhen BinDeBio Ltd.

Kite, A Gilead Company

Sumitomo Pharma America, Inc.

In8bio Inc.

Fate Therapeutics

Sichuan Baili Pharmaceutical Co., Ltd.

Janssen Research & Development, LLC

Medolution Ltd.

Kymera Therapeutics, Inc.

Kite, A Gilead Company|Gilead Sciences

Newave Pharmaceutical Inc

Servier

Meryx, Inc.

Armaceutica, Inc.

Hangzhou Qihan Biotech Co., Ltd.

Nanjing Bioheng Biotech

Sanofi

Syndax Pharmaceuticals

Vincerx Pharma, Inc.

Key Products

Orca-T

CPX-351

TGRX-814

UCART22

ADCT-602

Anti-CD19 Universal CAR-T Cells

BEAM-201

BinD19

Brexucabtagene autoleucel

DSP-5336

EAGD T-cell infusion

FT819

GNC-035

GNC-038

JNJ-75276617

Keynatinib

KT-253

KTE-X19

LP-118

LP-108

S95014

MRX-2843

Pyronaridine Tetraphosphate

QN-019a

RD13-02

SAR443579

SNDX-5613

VIP943

Please Note: It will take 3-5 business days to complete the report upon order confirmation.